86.22.Z - Specialist medical practice activities
68.10.Z - Buying and selling of own real estate
72.11.Z - Research and experimental development on biotechnology
72.19.Z - Other research and experimental development on natural sciences and engineering
85.42.B - Colleges
85.60.Z - Educational support activities
86.10.Z - Hospital activities
86.21.Z - General medical practice activities
86.90.C - Nurses and midwives activities
86.90.E - Other human health activities notelsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Profit (loss) on sale | -15,8 | |||
Gross profit (loss) | 0,4 | 0,3 | 0,3 | -6,5 |
EBITDA | 0,7 | 0,6 | 0,6 | -11,9 |
Short time liabilities | 0,4 | 0,4 | 0,4 | -5,3 |
Other operating costs | -20,1 | |||
Equity capital | 2,5 | 2,4 | 2,3 | -1,7 |
Operating profit (EBIT) | 0,4 | 0,3 | 0,3 | -6,1 |
Assets | 2,9 | 2,8 | 2,8 | 1,3 |
Net profit (loss) | 0,4 | 0,3 | 0,3 | -6,5 |
Cash | 1,1 | 0,8 | 1 | 17,4 |
Liabilities and provisions for liabilities | 0,4 | 0,4 | 0,5 | 18,3 |
Net income from sale | 6,8 | 7,8 | 8 | 2,7 |
Working assets | 1,2 | 0,9 | 1 | 21,1 |
Other income costs | 3535,5 | |||
Depreciation | 0,3 | 0,3 | 0,3 | -17,1 |
% | % | % | p.p. | |
Profitability of capital | 15,8 | 11,5 | 10,9 | -0,6 |
Equity capital to total assets | 86,4 | 85,2 | 82,7 | -2,5 |
Gross profit margin | 6,4 | 3,9 | 3,5 | -0,4 |
EBITDA Margin | 10,6 | 8,3 | 7,1 | -1,2 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 21 | 19 | 18 | -1 |
Current financial liquidity indicator | 2.9171268939971924 | 2.0584311485290527 | 2.632026195526123 | 0,5 |
Net dept to EBITDA | -1.5623728036880493 | -1.2719980478286743 | -1.5221256017684937 | -0,2 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane